BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company's stock has suffered the last few days, largely, it seems, due to two of its major products not being on the just released LCD coverage list. There's more to the story, and we reiterate our recently upgraded price target.
